Pancreatic stone protein testing market seen growing at 7.8% CAGR by 2030

The pancreatic stone protein testing market is projected to rise from $1.22 billion in 2025 to $1.77 billion by 2030, driven by sepsis detection, point-of-care testing and hospital infection concerns. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Pancreatic stone protein testing is becoming a sharper tool for spotting sepsis and systemic inflammation earlier in hospitals and emergency care. - The market outlook points to steady demand for faster diagnostics as hospitals face more infections, more point-of-care testing and more pressure to improve critical-care decisions. - The Business Research Company projects the market to reach $1.77 billion by 2030, up from $1.22 billion in 2025.

What happened: - The Business Research Company released a 2026 report on the pancreatic stone protein testing market on July 6, 2026. - The report says the market will grow to $1.31 billion in 2026, from $1.22 billion in 2025, at a 7.5% CAGR. - The report forecasts a 7.8% CAGR from 2026 to 2030. - The report points to rising demand for early sepsis detection, point-of-care diagnostics, precision medicine, automated lab systems and diagnostic innovation in critical care. - The report says North America held the largest market share in 2025. - The report expects Asia-Pacific to grow fastest during the forecast period.

The details: - Pancreatic stone protein testing measures a biomarker produced by the pancreas and other tissues during physiological stress or cellular dysfunction. - The test is used to assess systemic inflammatory responses and tissue stress. - The report says the test helps monitor critical conditions such as sepsis. - Hospital-acquired infections are a major growth driver for the market. - Antimicrobial resistance is making hospital infection control harder. - PSP testing supports earlier infection detection and sepsis-risk assessment, which can help clinicians act sooner. - Data from the Australian Institute of Health and Welfare showed hospital-acquired complications in 115,000 public hospitalizations and 34,200 private hospitalizations in 2022–23. - Healthcare-associated infections accounted for 37% of those complications. - Point-of-care testing is also expanding the market because it delivers results closer to the patient. - The American Association for Clinical Chemistry reported a 12.4% increase in point-of-care diagnostic testing adoption in hospitals and outpatient facilities in 2024 compared with 2023. - The report says PSP testing is moving into emergency and critical care workflows. - Rapid immunoassay platforms and multiplex biomarker panels are also gaining traction. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa. - The company offers a free sample of the market report and the full market report.

Between the lines: - The report frames PSP testing as part of a broader shift toward earlier, decentralized diagnosis in acute care. - The growth case depends less on one single clinical use and more on several converging trends, including sepsis screening, hospital infection pressure and point-of-care adoption. - North America’s lead suggests strong uptake in advanced health systems, while Asia-Pacific’s faster growth suggests broader expansion from a smaller base.

What's next: - PSP testing adoption is likely to track hospital investment in rapid diagnostics, automated systems and critical-care workflows. - Market growth will likely stay tied to infection rates, emergency-care demand and the spread of portable testing platforms. - Multiplex biomarker panels could become a larger part of future product development as labs look to combine PSP with other inflammation markers.

The bottom line: - Pancreatic stone protein testing is moving from a niche biomarker toward a broader diagnostic role, and the market is positioned for sustained growth through 2030.